Biohaven’s Strategic Advances and Promising Data Drive Buy Rating

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd., with a price target of $50.00.

Tyler Van Buren has given his Buy rating due to a combination of factors including Biohaven’s strategic preparations and promising clinical data. The company is gearing up for an Advisory Committee meeting for its drug ‘Vyxglia’ in Spinocerebellar Ataxia (SCA), with a PDUFA date anticipated in mid-November. The administration’s focus on providing treatment options for severe conditions could favorably impact Biohaven’s prospects.
Additionally, Biohaven’s New Drug Application for troriluzole is under Priority Review, with the company having completed site inspections successfully. The management’s confidence is bolstered by data showing significant reductions in disease progression and falls in patients. Furthermore, Biohaven is actively preparing for a potential U.S. launch by building a commercialization team and leveraging relationships with key opinion leaders, despite discontinuing development of troriluzole for Obsessive-Compulsive Disorder due to lack of efficacy.